NCT02880319: Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone

NCT02880319
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: Bone
Additional Notes: 
Exclusions: 
https://ClinicalTrials.gov/show/NCT02880319

Comments are closed.

Up ↑